This site is intended for health professionals only

Published on 7 November 2012

Share this story:
Twitter
LinkedIn

Vortioxetine filed in the US and EU

teaser

H. Lundbeck A/S (Lundbeck) reports revenue of DKK 3,563 million for the third quarter of 2012, excluding Lexapro® in the US, an increase of 2% compared to the same period last year. EBITDA and EBIT were DKK 846 million and DKK 661 million respectively, corresponding to an EBITDA margin of 23.4% and an EBIT margin of 18.2%. Profits were affected by the increase in launch costs associated with Lundbeck’s newer products, as well as the loss of revenue from Lexapro due to generic competition.
To read the rest of the report click on the link:
newsclient.omxgroup.com:443/cds/DisclosureAttachmentServlet?showInline=true&messageAttachmentId=409046
 


Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story:
Twitter
LinkedIn